

BFW



PATENT
ATTORNEY DOCKET NO.: 053529-5007-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
)
Berkley LYNCH *et al.*)
)
Application No.: 10/725,189) Group Art Unit: 1711
)
Filed: December 2, 2003) Examiner: Unassigned
)
FOR: METHODS FOR THE IDENTIFICATION)
OF AGENTS FOR THE TREATMENT OF)
SEIZURES, NEUROLOGICAL DISEASES,)
ENDOCRINOPATHIES AND HORMONAL)
DISEASES)

Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents

do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: September 23, 2004
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
SPT:mk

By:


Sally P. Teng, Ph.D.
Registration No. 45,397
Tel. No.: (202) 739-5734
Fax No.: (202) 739-3001

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT
 BY APPLICANT**

Attorney Docket No. 053529-5007-01
 Client Ref.

Applicant: Berkley LYNCH *et al.*

Appln. No.: 10/725,189

Filing Date: December 2, 2003

Examiner: Unassigned Group Art Unit: 1711

Page 1 of 2

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	20030009024 A1	01/09/2003	Curtis			
BR	20020142383 A1	10/03/2002	Merkulov <i>et al.</i>			
CR						


FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name				
						Enclosed	No	Enclosed	No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
GR	Bajjalieh SM, <i>et al.</i> SV2, a brain synaptic vesicle protein homologous to bacterial transporters. <i>Science</i> 1992; 257(5074):1271-1273								
HR	Bajjalieh SM, <i>et al.</i> Brain contains two forms of synaptic vesicle protein 2. <i>Proc Natl Acad Sci (USA)</i> . 1993; 90(6):2150-2154								
IR	Bajjalieh SM, <i>et al.</i> Differential expression of synaptic vesicle protein 2 (SV2) isoforms. <i>J Neurosci</i> . 1994 ; 14(9):5223-5235								
JR	Buckley, K <i>et al.</i> Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. <i>J Cell Biol</i> . 1985; 100(4):1284-1294								
KR	Crowder, KM <i>et al.</i> Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). <i>Proc Natl Acad Sci (USA)</i> . 1999; 96(26):15268-15273								
LR	Feany, MB <i>et al.</i> The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. <i>Cell</i> . 1992; 70(5):861-867								
MR	Fuks, B, <i>et al.</i> Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. <i>European Journal of Pharmacology</i> 478 (2003) pp. 11-19								
NR	Hayashi, M <i>et al.</i> Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. <i>Adv Exp Med Biol</i> . 1999; 460:91-93								
OR	Janz, R <i>et al.</i> SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. <i>J Neurosci</i> . 1998; 18(22):9269-9281								
PR	Janz, R <i>et al.</i> SV2A and SV2B function as redundant Ca ²⁺ regulators in neurotransmitter release. <i>Neuron</i> . 1999; 24(4):1003-1016								
QR	Janz, R. Knockout mice and SV2 synaptic-vesicle proteins. <i>University of Texas Health Science Center at Houston Neuroscience Research Center Newsletter</i> , 2001; 7(3):1,4-5								
RR	Lynch B, <i>et al.</i> The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. <i>PNAS</i> , June 29, 2004, vol. 101, no. 26, pp. 9861-9866								

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)		Attorney Docket No.	Client Ref.
To: U.S. Department of Commerce Patent and Trademark Office		053529-5007-01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Berkley LYNCH <i>et al.</i>	
		Appln. No.: 10/725,189	
		Filing Date: December 2, 2003	
		Examiner: Unassigned	Group Art Unit: 1711
Page 2 of 2			



U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclosed	No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
	GR	Margineanu, DG <i>et al.</i> Levetiracetam: Mechanisms of action. In: Antiepileptic Drugs, 5th Edition. Levy, RH <i>et al.</i> eds. 2002; Lippincott Williams & Wilkins, Philadelphia, PA. Pp. 419-427							
	HR	Noyer, M <i>et al.</i> The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995; 286(2):137-146							
	IR	Pyle, RA <i>et al.</i> Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem. 2000; 275(22):17195-17200							
	JR	Schivell, AE <i>et al.</i> Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996; 271(44):27770-27775							
	KR	Son, Y-J <i>et al.</i> The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. J Biol Chem. 2000; 275(1):451-460							
	LR	Xu, T <i>et al.</i> SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001; 3(8):691-698							
	MR	Nagase <i>et al.</i> , Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> . DNA Research 5, 1998, 277-286							
	NR	Genbank Accession 094841, May 1, 1999, KIAA0736 Human SV2							
	OR								

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.